Intellect’s new approach specifically targets neoepitopes that are formed following cleavage of intact tau protein by executioner caspases.
The pathological process is stimulated by an accumulation of amyloid beta in the brain of Alzheimer’s patients.
Intellect’s approach uses antibodies to clear the more toxic form, without risk of interfering with the functions of normal intact tau protein.
Intellect chairman and CEO Daniel Chain said they are encouraged by two studies results suggesting that tau may cause Alzheimer’s disease to spread through the brain.